LENZ Therapeutics, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$12.74
−$0.75 (−5.53%) Close
Pre-market$13.23
+$0.49 (+3.81%) 10:11 PM ET
Prev closePrevC$13.49
OpenOpen$13.21
Day highHigh$13.21
Day lowLow$12.40
VolumeVol244
Avg volAvgVol1,021,347
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$422.10M
P/E ratio
-6.19
FY Revenue
$17.50M
EPS
-2.06
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
LENZ
LENZ Therapeutics, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−38% (Below avg)
Vol/Avg: 0.62×
RSI
41.63(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.02 (Strong)
MACD: 0.05 Signal: 0.03
Short-Term
+0.16 (Strong)
MACD: -1.35 Signal: -1.51
Long-Term
+0.08 (Strong)
MACD: -2.98 Signal: -3.06
Intraday trend score
47.00
LOW37.00HIGH61.00
Latest news
LENZ•6 articles•Positive: 0Neutral: 1Negative: 0
NeutralThe Motley Fool• Jesterai
Lenz (LENZ) Q2 Revenue Jumps 604%
Lenz Therapeutics reported $5.0 million in Q2 2025 revenue from licensing deals, exceeding analyst expectations. The company is preparing for FDA review of LNZ100, an eye drop for presbyopia, with a decision expected by August 8, 2025. Despite increased operating expenses leading to a wider net loss, Lenz remains focused on commercial readiness.
Mixed financial performance with unexpected licensing revenue, significant pre-launch investments, and pending FDA approval create a balanced outlook. The company shows strategic preparation but also faces increased expenses and uncertainty around market adoption.
UnknownGlobeNewswire Inc.• LENZ Therapeutics, Inc.
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
Capstone data from Phase 3 CLARITY study to be presented
LENZCalendar of Events
UnknownGlobeNewswire Inc.• LENZ Therapeutics, Inc.
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City.
LENZCalendar of Events
UnknownGlobeNewswire Inc.• LENZ Therapeutics, Inc.
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024
LENZEarnings Releases and Operating Results
UnknownGlobeNewswire Inc.• Lenz Therapeutics, Inc.
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update.
LENZCalendar of EventsConference Calls/ Webcasts
UnknownBenzinga• Vandana Singh
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101.
Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity.
Citi analyst writes that with promising Phase 3 ...Full story available on Benzinga.com
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
